1620 Investment Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

1620 Investment Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25	Closed	–	–	720
2025 Q1	$0	Hold	25	–	–	﹤0.01%	726
2024 Q4	$0	Hold	25	–	–	﹤0.01%	762
2024 Q3	$0	Hold	25	–	–	﹤0.01%	724
2024 Q2	$0	Buy	+25	New	–	﹤0.01%	596

1620 Investment Advisors's SGYP Position: Q2 2025 in Review

1620 Investment Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2025, closing a stake of 25 shares.

1620 Investment Advisors first reported a position in SGYP in Q2 2024 and held it in 4 quarters. The position peaked at $0 in Q1 2025. 0 funds tracked by Wall St. Rank hold SGYP as of Q2 2025.

1620 Investment Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2025 after selling out during the quarter.
1620 Investment Advisors sold 25 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2025.
1620 Investment Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2024 and held it in 4 quarters.
1620 Investment Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $0 in Q1 2025.
0 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2025.

Based on 1620 Investment Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.